Firefly Neuroscience Teams With German Hospital to Study Rare Brain Disorders Using AI and EEG

Author: Benzinga Newsdesk | July 14, 2025 07:47am

Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ:AIFF), an Artificial Intelligence ("AI") company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to highlight its ongoing collaboration with Prof. Dr. med. Christian Schaaf, Director of the Institute of Human Genetics at Heidelberg University Hospital and Chairman of Human Genetics at the Medical Faculty of Heidelberg University, on a groundbreaking study investigating the neurophysiological impact of 15q13.3 copy number variants ("CNVs"). This engagement builds on prior work between Firefly and Prof. Schaaf, including a joint publication on CHRNA7-related phenotypes.1

The current study leverages Firefly's FDA-cleared technology to analyze Electroencephalograms ("EEG") data from 30 subjects — 15 with deletions and 15 with duplications of the 15q13.3 chromosomal region. Study subjects undergo resting state and two cognitive paradigms running automatically through Firefly's BNA platform.

The study is scheduled to run through 2026, with Firefly commercially engaged to provide EEG systems, training, and full analytic support, including the comparison to its proprietary, FDA-cleared normative Resting and Event-Related Potential Cognitive tasks database.

The study aims to:

1. Identify electrophysiological biomarkers associated with 15q13.3 CNVs;
2. Characterize neurocognitive profiles linked to deletions vs. duplications; and
3. Support future diagnostic and therapeutic strategies for neurodevelopmental disorders.
   
    

Posted In: AIFF